Development and Validation of the Continuous Subcutaneous Insulin Infusion-Related Quality-of-Life (CSII-QOL) Scale

Sakane, Naoki; Murata, Takashi; Tone, Atsuhito; Kato, Ken; Kimura, Moritsugu; Kawashima, Seiichiro; Sawaki, Hideaki; Hirota, Yushi; Okada, Akira; Kuroda, Akio; Matsuhisa, Munehide; Watanabe, Tomokazu; Suganuma, Akiko; Nirengi, Shinsuke; Toyoda, Masao

doi:10.1089/dia.2019.0216

Cited by 6 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also used the recently developed CSII-QOL score, which was created to assess the QOL specifically related to CSII. 14 Better adherence to CGM was associated with worse CSII-related QOL, especially with psychological problems, which suggests that participants who had unmet needs in the self-management of T1D, even after starting CSII, might have wanted to perform CGM more constantly.…”

Section: Discussionmentioning

confidence: 99%

“…To assess the QOL, the Hypoglycemia Fear Survey (HFS; HFS-B for behavior, HFS-W for worry) was used to evaluate the fear of hypoglycemia, Problem Areas in Diabetes (PAID; 20 items) was used to evaluate the emotional burden of diabetes, the Euro-QOL 5 dimensions 3-level version (EQ-5D-3L) utility score was used to measure the functional health status, and CSII-QOL (convenience factor, social restriction factor, and psychological problems factor) was used to evaluate the QOL in relation to CSII. 11-14 A higher HFS score indicates worse fear of hypoglycemia, a higher PAID score indicates a heavier emotional burden of diabetes, a lower EQ-5D-3L score indicates a poorer functional health status, and a lower CSII-QOL score indicates worse CSII-related QOL. All of the psychometric evaluations were conducted in Japanese.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Predictive Factors of the Adherence to Real-Time Continuous Glucose Monitoring Sensors: A Prospective Observational Study (PARCS STUDY)

Murata

Kuroda

Matsuhisa

et al. 2020

J Diabetes Sci Technol

Self Cite

View full text Add to dashboard Cite

Background: Information about factors related to better adherence to continuous glucose monitoring (CGM) sensor adherence is quite limited. Materials and Methods: Forty-six participants with type 1 diabetes using continuous subcutaneous insulin infusion (CSII) without CGM were recruited. The participants’ characteristics and diabetes-related quality of life (QOL) were evaluated at baseline and one year after starting to use CGM. Participants wearing the sensor for ≥60% of the time were considered as adherent. Results: The mean age of the 46 participants was 44.1 ± 15.0 years old and the mean glycohemoglobin (HbA1c) was 7.7 ± 1.0%; 60.9% of the participants were classified as adherent. The duration of using CSII was longer in the adherent group, and the degree of diabetic retinopathy was significantly different. There were no significant differences in age, frequency of self-monitoring of blood glucose, or Hypoglycemia Fear Survey (HFS-B for behavior, HFS-W for worry) score at baseline between the adherent and nonadherent groups. The Problem Areas in Diabetes (PAID) score at baseline was significantly higher and the total CSII-QOL score at baseline was significantly lower in the adherent group. The usage of dual-wave bolus was significantly increased in the adherent group (34.6%-61.5%, P = .016), but not in the nonadherent group (33.3%-33.3%, P > .999). The HbA1c level showed a significant improvement in the adherent group (7.8%-7.3%, P < .001), but not in the nonadherent group (7.5%-7.2%, P = .102). Conclusions: Higher adherence to CGM sensors may be associated with a heavier emotional burden of diabetes and a worse QOL in relation to CSII at baseline.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Predictive Factors of the Adherence to Real-Time Continuous Glucose Monitoring Sensors: A Prospective Observational Study (PARCS STUDY)

Murata

Kuroda

Matsuhisa

et al. 2020

J Diabetes Sci Technol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Al follow-up, oltre a eseguire la valutazione clinica, viene somministrato alla paziente il questionario Continuous Subcutaneous Insulin Infusion-Related Quality of Life (CSII-QoL) Scale, per approfondire l'impatto della CSII sulla QoL (Tab. IV) (32).…”

Section: Caso Clinico Nunclassified

“…Al follow-up viene somministrato ai genitori della bambina il questionario Continuous Subcutaneous Insulin Infusion-Related Quality of Life (CSII-QoL) Scale (Tab. IV) (32). Dall'analisi dei fattori prevalenti (Tab.…”

Section: Caso Clinico Nunclassified

“…glucose monitoring; CV = coefficiente di variazione; HbA1c = emoglobina glicata; Nd = non disponibile; SD = standard deviation; TAR = time above range; TBR = time below range; TIR = time in range.TABELLA IV -Questionario Continuous Subcutaneous Insulin Infusion-Related Quality of Life (CSII-QoL) -Scala di valutazione a 5 punti su 28 domande [elaborata da(32)]0 = fortemente in disaccordo 1 = in disaccordo 2 = né in disaccordo né in accordo 3 = d'accordo 4 = fortemente d'accordoPaziente La terapia con microinfusore è utile per correggere le iperglicemie Dalla seguente analisi sono state escluse le domande n. 6, 11 e 15. TABELLA V -Questionario ad hoc sul livello di soddisfazione degli utilizzatori Sulla seguente scala, valutare il proprio livello di soddisfazione per ciascuna delle caratteristiche sottoelencate 1 = molto insoddisfatto 2 = insoddisfatto 3 = né insoddisfatto né soddisfatto 4 = soddisfatto 5 = molto soddisfatto Paziente Sulla seguente scala, indicare il livello di importanza che ciascuna delle caratteristiche sottoelencate riveste per sé 1 = estremamente irrilevante 2 = irrilevante 3 = né importante né non importante 4 = importante 5 = estremamente importante Paziente…”

unclassified

See 1 more Smart Citation

Beyond the barriers of the use of continuous subcutaneous insulin therapy in type 1 diabetes: a new opportunity from catheter-less insulin pumps

Esposito

Bolla

Costantino

et al. 2021

abtpn

View full text Add to dashboard Cite

Although it represents a valid alternative for patients with type 1 diabetes (T1DM) with insufficient glycemic control and/or with recurrent hypoglycemia, insulin pump therapy (Continuous Subcutaneous Insulin Infusion, CSII) in Italy is nowadays still relatively uncommon. The following review aims to investigate the barriers that limit the transition to CSII and the reasons behind the widespread cases of drop-out, particularly evident in younger patients. Among the interventions that could contribute to the solution of the problem, catheter-less insulin pumps (or patch-pumps) will be described: a tool potentially able to reduce, if not eliminate, some of the main obstacles encountered by patients. In particular, a new opportunity has become available today thanks to the evolution of the generation of catheter-less insulin pumps represented by Accu-Chek® Solo (Roche Diabetes Care GmbH), therefore three clinical cases of patients with T1DM undergoing therapy with the Accu-Chek® Solo insulin pump will be presented and discussed herein.

show abstract

Glycometabolic outcomes in adult type 1 diabetic patients switching to closed-loop systems

Papa,

Cannarella,

Condorelli

et al. 2023

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Development and Validation of the Continuous Subcutaneous Insulin Infusion-Related Quality-of-Life (CSII-QOL) Scale

Cited by 6 publications

References 23 publications

Predictive Factors of the Adherence to Real-Time Continuous Glucose Monitoring Sensors: A Prospective Observational Study (PARCS STUDY)

Predictive Factors of the Adherence to Real-Time Continuous Glucose Monitoring Sensors: A Prospective Observational Study (PARCS STUDY)

Beyond the barriers of the use of continuous subcutaneous insulin therapy in type 1 diabetes: a new opportunity from catheter-less insulin pumps

Glycometabolic outcomes in adult type 1 diabetic patients switching to closed-loop systems

Contact Info

Product

Resources

About